How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance. by Casson, Steven G et al.
Casson, SG; Ruiz, FJ; Miners, A (2013) How long has NICE taken
to produce Technology Appraisal guidance? A retrospective study to
estimate predictors of time to guidance. BMJ Open, 3 (1). e001870.
ISSN 2044-6055
Downloaded from: http://researchonline.lshtm.ac.uk/610210/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
How long has NICE taken to produce
Technology Appraisal guidance?
A retrospective study to estimate
predictors of time to guidance
Steven G Casson,1 Francis J Ruiz,2 Alec Miners1,3
To cite: Casson SG, Ruiz FJ,
Miners A. How long has NICE
taken to produce Technology
Appraisal guidance?
A retrospective study to
estimate predictors of time to
guidance. BMJ Open 2013;3:
e001870. doi:10.1136/
bmjopen-2012-001870
▸ Prepublication history for
this paper are available
online. To view these files
please visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2012-001870).
Received 26 July 2012
Revised 7 December 2012
Accepted 10 December 2012
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
1London School of Hygiene
and Tropical Medicine,
London, UK
2NICE International, National
Institute for Health and
Clinical Excellence, London,
UK
3Department of Health
Services Research and Policy,
London School of Hygiene
and Tropical Medicine,
London, UK
Correspondence to
Dr Steven G Casson;
steve.casson@cantab.net
ABSTRACT
Objectives: To assess how long the UK’s National
Institute for Health and Clinical Excellence’s (NICE)
Technology Appraisal Programme has taken to produce
guidance and to determine independent predictors of
time to guidance.
Design: Retrospective time to event (survival)
analysis.
Setting: Technology Appraisal guidance produced by
NICE.
Datasource: All appraisals referred to NICE by
February 2010 were included, except those referred
prior to 2001 and a number that were suspended.
Outcome measure: Duration from the start of an
appraisal (when the scope document was released)
until publication of guidance.
Results: Single Technology Appraisals (STAs) were
published significantly faster than Multiple Technology
Appraisals (MTAs) with median durations of 48.0 (IQR;
44.3–75.4) and 74.0 (IQR; 60.9–114.0) weeks,
respectively (p <0.0001). Median time to publication
exceeded published process timelines, even after
adjusting for appeals. Results from the modelling
suggest that STAs published guidance significantly
faster than MTAs after adjusting for other covariates
(by 36.2 weeks (95% CI −46.05 to −26.42 weeks))
and that appeals against provisional guidance
significantly increased the time to publication (by
42.83 weeks (95% CI 35.50 to 50.17 weeks)). There
was no evidence that STAs of cancer-related
technologies took longer to complete compared with
STAs of other technologies after adjusting for
potentially confounding variables and only weak
evidence suggesting that the time to produce guidance
is increasing each year (by 1.40 weeks (95% CI −0.35
to 2.94 weeks)).
Conclusions: The results from this study suggest that
the STA process has resulted in significantly faster
guidance compared with the MTA process irrespective
of the topic, but that these gains are lost if appeals are
made against provisional guidance. While NICE
processes continue to evolve over time, a trade-off
might be that decisions take longer but at present there
is no evidence of a significant increase in duration.
INTRODUCTION
In England and Wales, the primary role of
National Institute for Health and Clinical
Excellence’s (NICE’s) Centre for Health
Technology Evaluation is to produce guid-
ance on the appropriate use of technologies
for the National Health Service (NHS). Prior
to 2005 all appraisals were undertaken using
its Multiple Technology Appraisal (MTA)
process.1 However, following criticism of the
slow production of guidance,2 3 NICE estab-
lished the Single Technology Appraisal
(STA) process in 2005 with the objective of
producing faster guidance closer to the time
of product launch.4 5 Both processes
produce determinations intended to guide
ARTICLE SUMMARY
Article focus
▸ How long have National Institute for Health and
Clinical Excellence’s Technology Appraisals
taken to produce guidance?
▸ What features of an appraisal independently
predict the time to publication of guidance?
Key messages
▸ The Single Technology Appraisal (STA) process
has reduced the time to publication by about
36 weeks irrespective of the topic.
▸ Appeals against final appraisal determinations
have more than doubled the time it takes for
STAs to conclude. No other factors were
strongly predictive of the time to guidance.
▸ No variables predicting the likelihood of an
appeal were identified.
Strengths and limitations of this study
▸ Use of time to event analysis is a significant
improvement upon previous studies addressing
the primary question.
▸ Other factors might also independently predict
the time to guidance, such as consideration of
patient access schemes and the number of con-
sultees on each appraisal.
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decisions on technology adoption. Both respond to the
challenge of uncertainty which already exists (but has
not previously been addressed) or which has been pro-
duced by the arrival of a novel technology or new evi-
dence. MTAs and STAs are largely identical in structure
(but not scheduling) with the exception of the subpro-
cess which assesses the evidence of effectiveness and
cost-effectiveness. The substantive differences therein
are ﬁrst, the party responsible for the assessment, and
second, the scope of the analysis. In MTA, independent
reviewers produce a comparative analysis of technologies
for an indication and manufacturers also submit assess-
ments. However in STAs, manufacturers’ submissions are
limited to the consideration of a single technology and
the independent review is restricted to a critique of this
submission. Precise details of both processes can be
found elsewhere;1 6 STA adoption has been rapid,
increasing from 13% of all technology appraisals in June
2008 to 43.4% by February 2010.
STAs and MTAs should in theory take 43 and 60 weeks,
respectively, to conclude in the absence of an appeal
against the provisional guidance (more formally known
as a ‘ﬁnal appraisal determination’). A number of studies
have attempted to assess whether the processes have met
these targets and whether the STA process has resulted in
faster guidance.7–9 For example, Ford et al8 suggest that
the STA has reduced the time to produce guidance, but
not for cancer-related technologies. O’Neill et al9 also
suggest that the STA has reduced the average time to
guidance, by approximately 1 year. However, both ana-
lyses are limited. First, Ford considers the time from
product launch to guidance, rather than choosing a start-
ing point on or after the point at which NICE assumes
full control, and that is the date on which NICE is for-
mally requested to appraise a technology by the
Department of Health. NICE has only limited inﬂuence
on the request date from the Department of Health.
Second, the studies only include completed appraisals;
no adjustments were made for ongoing, and potentially
lengthy, assessments. This means that the results could be
biased. Third, while Ford and O’Neill attempted to iden-
tify independent predictors of the time to guidance,
none assessed these using formal statistical approaches
for time to event data. Finally, no attempts were made to
formally identify the individual contribution of each
explanatory variable to the total time. The purpose of
this study is to address all of these issues.
METHODS
Inclusion criteria
All appraisals referred to NICE by February 2010 were
considered for inclusion. However, MTAs prior to 2001
were excluded as they followed a different process to
recent MTAs. Appraisals were also excluded (19 STAs
and 7 MTAs) if they had been suspended or postponed
following initial referral from the Department of Health
but before NICE issued the ﬁnal scope document.
Key dates, durations and data sources
Data for the analysis were taken from NICE’s website.
A small amount of missing data (comprised of 21 start
dates, 6 suspension dates, 4 appeal announcement dates
and 6 process types, ie, MTA or STA) was provided dir-
ectly by NICE, on request. The ‘core’ appraisal time
period was bounded as follows. Start dates were calcu-
lated for the majority of appraisals using the ‘ﬁnal
scope’ date, as this was the earliest consistently recorded
time point available throughout the whole dataset. This
date is also in line with when NICE ‘starts the clock’.
The scope documents issued include information on
the intervention(s) to be evaluated and the relevant
comparator programmes. The time of scope document
release can be viewed as a formal appraisal start date for
the purposes of inviting and constructing evidenced
based submissions. Where this date was unknown (for
1 STA and 6 MTAs), the start date was inferred using the
‘closing date for submissions to appraisal process by con-
sultees’. This time point is scheduled to occur at week 9
in the STA process or week 14 for a MTA. Subtraction of
the relevant number of weeks (9 or 14) allowed the start
of the core process to be inferred.
Statistical analysis
The data were analysed using time to event (survival)
analysis techniques with the ‘event’ being publication of
guidance. Time to publication was initially assessed
using Kaplan-Meier (KM) techniques, stratiﬁed by the
parameter of interest (eg, STA/MTA process). Statistical
signiﬁcance was estimated using the log-rank test. The
end (censor) date was taken to be the date ﬁnal guid-
ance was published, the date an appraisal was suspended
or 13 February 2010 (the end of the data collection
period), whichever occurred ﬁrst. Rather than using
Cox proportional hazard models to adjust KM results for
multiple independent parameters, parametric techni-
ques were instead used. This was because the latter is
able to generate predictions of time to publication of
guidance for censored events, and to provide direct esti-
mations of the independent contribution of each pre-
dictive variable to the total time to guidance (ie, the
marginal effect). For example, the number of weeks an
appeal has added to the length of a MTA or STA can be
calculated, all other factors held constant. A number of
different parametric time to event models were ﬁtted to
the data including exponential, Weibull, lognormal,
loglogistic, Gompertz and γ. The model that minimised
Akaike’s information criterion was selected for use.
Sensitivity analysis was also used to assess the effect of
using alternative parametric model forms. Additionally,
logistic regression was used to assess whether a number
of independent variables predicted the likelihood of an
appeal. The proportion of appraisals completing within
anticipated process times (43 and 60 weeks for STAs and
MTAs) were assessed by assuming a binomial distribu-
tion. All analyses were undertaken using STATAV.12.
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Choice of independent variables
The choice of appraisal process (STA or MTA) was an
obvious parameter for inclusion, since STAs are
designed to be shorter than MTAs. Other parameters
were identiﬁed using the existing literature and consid-
eration of the underlying processes. For example, it is
logical that an appeal against provisional guidance could
add substantially to the time it takes to publish ﬁnal
guidance. Other authors have also suggested that cancer
appraisals are typically more complex and ‘controver-
sial’, given that they tend to be associated with high
incremental cost-effectiveness ratios, meaning they take
longer to complete. NICE considers revising published
appraisal guidance every 1–3 years. Given that in theory
such revisions should be adding to an existing evidence
base, it was suspected that these might take a shorter
time to complete compared with other appraisals.
O’Neill suggested that there was no evidence that
appraisals are generally taking longer to complete, a so
called ‘time-trend’. However, O’Neill also suggests that
this conclusion should be revisited using more formal
statistical approaches.
For these reasons, the following independent variables
were included in the time to event analysis and logistic
regression analysis: review of an existing appraisal (yes/
no), drug (yes/no), cancer-related topic (yes/no),
whether an appeal on the ﬁnal appraisal determination
(yes/no), calendar year of appraisal start (2001–2010)
and an interaction term between STA and cancer to test
whether there was a difference between cancer-related
and remaining STAs.
Other parameters were considered for inclusion, some
of which had previously been studied. These included
consideration of patient access schemes, guidance that
ultimately restricted the use of a technology and the
number of groups (consultees) who were formally
engaged with an appraisal. However, such parameters
were rejected from the ﬁnal model because of difﬁcul-
ties in consistently collecting this evidence. For example,
a number of patient access schemes have been submit-
ted to NICE, but only more recently has this become a
formal part of NICE’s appraisal processes.
The basic tested hypothesis was that none of the para-
meters independently predicted the time to publication
of guidance.
RESULTS
Data were collected on 196 appraisals, 80 STAs and 116
MTAs that started between 2001 and 2010 (table 1). All
but one STA appraised the use of drugs, and almost
40% of all appraisals were cancer related. Approximately
half of the STAs had been published (39/80) by the
time of analysis, as had 84% (97/116) of the MTAs.
Over 20% (45/196) of the appraisals included at least
one appeal and 15% (29/196) were reviews of existing
guidance.
The estimates of process length for completed STAs
(published on time: 9/39=23%, p = 0.001) and MTAs
(19/97=20%, p<0.001) exceeded NICE’s timetabled
targets of 43 and 60 weeks, respectively, with the corre-
sponding median times of 45.4 (IQR 43.3–55.9) and
69.6 weeks (IQR 60.9–111.1). The proportion of apprai-
sals from both processes continued to exceed published
timelines after removing appraisals containing appeals
(p <0.01 in both instances), although the median times
were much closer to target levels (STA median
44.8 weeks, IQR 42.3–48.0; MTA median 61.6 weeks, IQR
57.7–71.1).
Results from the KM analysis showed that production
of guidance was signiﬁcantly faster for STAs than for
MTAs; the median time to guidance was 48.0 weeks
(IQR 44.3–75.4) and 74 weeks (IQR; 60.9–114.0) for the
STA and MTA processes, respectively, (p value<0.0001,
ﬁgure 1). Further stratiﬁed analysis (table 2) suggested
that appeals signiﬁcantly extended the time to guidance
for both MTAs and STAs (p <0.001), and that cancer-
related STAs were signiﬁcantly longer compared with
non-cancer STAs (p=0.02). None of the remaining com-
parisons were statistically signiﬁcant.
Table 1 Appraisals included in the analysis (n =196)
Variable STA MTA
N 80 116
Guidance published* 39 97
Appraisal suspended* 8 14
Appraisal of a drug or drugs 79 73
Appraisal cancer-related 47 29
At least one appeal† 9 36
Review 3 26
*At the time the analysis was undertaken.
†Appeals are made by consultees (often the producer of the
technology) against final appraisal determinations, that is, NICE’s
provisional guidance.
MTA, Multiple Technology Appraisal; NICE, National Institute for
Health and Clinical Excellence; STA, Single Technology
Appraisal.
Figure 1 Kaplan-Meier time to event estimate of time to
publication of guidance.
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Results from the multivariate parametric modelling
suggested that the loglogistic model was the most appro-
priate to use. STA and appeals were shown to be asso-
ciated with faster and slower times to guidance,
respectively, (table 3). None of the remaining variables
were signiﬁcantly associated with the time to guidance
although there was weak evidence of a yearly increase in
the time it has taken to publish guidance (1.40 weeks
(95% CI −0.35 to 2.94 weeks)). Sensitivity analysis using
different distributional forms had negligible effects on
the results. None of the covariates were found to be pre-
dictive of the likelihood of an appeal (data not shown).
DISCUSSION
The results from this analysis show that NICE’s STA
process produced much faster guidance to the NHS
compared with the MTA process, by about 36 weeks. But
appeals against provisional guidance, when they
occurred, more than offset this gain. The results from
the KM analysis suggested that cancer-related STAs were
longer than non-cancer STAs. However, the difference
was no longer statistically signiﬁcant when adjustments
were made for other variables. The evidence that each
year appraisal length is independently increasing is weak
at best (increase of 1.40 weeks (95% CI −0.35 to
2.94 weeks)). Variables indicating whether a technology
was a drug or a review of existing guidance were not pre-
dictive of the time to guidance.
How does this compare with other studies?
The percentages of MTAs and STAs completing within
timetabled targets are consistent with those reported by
O’Neill et al.9 While the estimates of STA duration were
also similar, the time taken to produce MTAs was not;
O’Neill and colleagues stated an average duration of
about 100 weeks whereas our unadjusted estimate was
nearer to 74 weeks indicating a much smaller difference
between the two process types. It is possible that meth-
odological differences could explain these ﬁndings. For
example, MTAs appraise the use of more than one tech-
nology. O’Neill considered each technology within a
MTA to represent a discrete decision, thus an appraisal
with three recommendations was effectively taken to be
equivalent to three appraisals. In this study each
appraisal was taken to represent a single event irrespect-
ive of the number of recommendations it contained.
However, irrespective of the best approach, it should be
noted that NICE clearly states published timelines repre-
sent a minimum amount of time to publication and that
the median times were within 2 weeks of target levels
Table 3 Results from the loglogistic modelling
Variable Coefficient 95% CI p Value Marginal effect (weeks)‡ 95% CI
STA* −0.49 −0.62 to −0.36 <0.001 −36.2 −46.05 to −26.42
Cancer* −0.03 −0.002 to 0.04 0.60 −2.06 −9.80 to 5.70
STA × cancer 0.13 −0.05 to 0.30 0.15 9.23 −3.36 to 21.81
Drug* 0.08 −0.01 to 0.20 0.08 6.10 −0.75 to 12.87
Review* −0.04 −0.12 to 0.07 0.43 −3.26 −11.39 to 4.87
Ever an appeal* 0.60 0.50 to 0.67 <0.001 42.83 35.50 to 50.17
Year started† 0.02 −0.002 to 0.04 0.073 1.40 −0.35 to 2.94
Ln_γ −2.06 −2.20 to −1.91 <0.001 − −
Log likelihood=2.23; constant=4.04.
*Yes=1, no=0.
†Where values range between (200)1 and (20)10.
‡Indicates the independent contribution to the median to time to publication; values less than 0 indicate that variables are associated with a
shorter time to guidance.
Table 2 Results of Kaplan-Meier analysis (weeks), log-rank tests of equality of survivor functions
MTA, n=116 STA, n=80
Strata N Median (IQR) p Value N Median (IQR) p Value
Cancer 23 66.5 (60.6–111.1) 18 57.0 (42.3–87.9)
No cancer 74 74.0 (61.4–116.1) 0.43 21 45.4 (44.7–55.7) 0.02
Review 17 68.4 (61.4–111.1) 1 44.1 (N/A)
Non-review 80 74.0 (60.9–116.4) 0.65 38 51.0 (44.7–75.4) 0.18
Drug 59 77.6 (62.4–116.3) 39 48.0 (44.3–75.4)
Non-drug 38 66.6 (57.7–91.8) 0.11 0 N/A -
Appeal* 35 116.1 (91.9–136.9) 7 76.7 (65.0–105.3)
No appeal 62 61.6 (57.7–71.1) <0.001 32 44.9 (42.3–48.0) <0.001
*Indicates at least one appeal.
MTA, Multiple Technology Appraisal; N indicates observed events; N/A, not applicable; STA, Single Technology Appraisal.
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when appraisals containing appeals were removed from
our analysis.
O’Neill et al9 reported that STAs were substantially
faster than MTAs. The unadjusted analysis of Ford et al8
also suggests that STAs have reduced the time to guid-
ance compared with MTAs, but not for STAs of cancer-
related technologies. We agree with the general ﬁnding
that the STA has signiﬁcantly reduced the time to guid-
ance. However, while our unadjusted KM analysis also
suggests STAs of cancer-related technologies were slower
to complete compared with their non-cancer related
counterparts, the difference was no longer signiﬁcant
when adjustments were made for other variables, includ-
ing appeals.
Both O’Neill and Ford include analyses that estimate
the time between product launch and production of
guidance by NICE, presumably because a speciﬁc object-
ive of the STA process is to minimise this time period.
However, our analysis used the point at which NICE
issued its ﬁnal scope as the appraisal starting point. We
elected not to use the time of product launch for a
number of reasons. First, the date is difﬁcult to measure
accurately and speciﬁcally, as there is no readily available
source of indication-speciﬁc license dates. Second, the
time from product launch to start of the NICE process is
largely outside of NICE’s control. Third, and perhaps
most importantly, the duration derived from the use of
the launch date often has little meaning. For example,
guidance on the use of vinorelbine for advanced breast
cancer (TA 54)10 was published in 2002, whereas its mar-
keting authorisation was issued in 1997, 2 years before
NICE existed.
O’Neill et al cautiously stated that there was no evi-
dence that either the STA or MTA have increased in
length over time. We agree with this conclusion.
Strengths and limitations
The main strength of this analysis compared with previ-
ous studies is that it uses formal time to event analysis
techniques to assess the time to publication of guidance.
In doing so, adjustments are made for potentially con-
founding variables and estimates of the marginal contri-
bution of each variable to the total time are generated.
This said, there are a number of limitations. First, the
start of each appraisal was taken to be the time at which
consultees are formally invited to submit evidence, set as
the time at which the ﬁnal scope document is issued. An
alternative viewpoint could be that since NICE consults
on scope documents, appraisals in some senses start
about 3 months earlier, even though there is no guaran-
tee during the consultation that the appraisal will
proceed. While including this extra time would increase
the median time to guidance, it is unlikely to alter the
predictive value of the explanatory variables. Second, no
account was taken of interruptions that were outside of
NICE’s control, such as public holidays or publication
embargos during general elections; the latter can be
lengthy. Third, MTAs usually result in guidance that
relates to the use of more than one technology. In this
analysis all appraisals have been treated as equal, in so
much that no account has been made of the number of
technologies being appraised. However, it is conceivable
that one MTA of (say) three technologies could be
shorter, in terms of calendar time, than three separate
STAs. This could mean that comparisons of the two pro-
cesses should be treated with some caution. Fourth,
there is a potential issue of endogeneity in the statistical
analysis since it is possible that appeals are at least partly
a result of the other independent variables. While this
cannot be completely ruled out, none of the examined
variables were independently predictive of an appeal,
thus we think this issue is unlikely to be important.
Lastly, although it is likely that other variables may be
related to the time to guidance, there are challenges in
quantifying them. One such example is the number or
mix of consultees, which could reﬂect the complexity/
level of interest in a particular area. We could not ﬁnd a
reliable method of quantifying this potential predictor
of time to guidance; patient groups often produce joint
submissions, and only the product manufacturer is ofﬁ-
cially a consultee in a STA.
It has also been suggested that the scale of the evi-
dence base could act as a predictor of duration.
However, the conceptual nature of any such relationship
is not clear. One hypothesis could be that where there
exists only a small number of trials, the time to guidance
would be shorter. However, Ford et al8 suggest an alter-
native hypothesis. They suggest that a limited evidence
base can produce uncertainties in cost-effectiveness data,
causing problems in setting start/stop prescribing rules.
Such a ‘challenge to the appraisal committee’ could
result in a request for further information and conse-
quential delays, that is, increased time to guidance. The
question of whether such an association exists would be
best answered using a range of qualitative and quantita-
tive methods and goes beyond the scope of this study.
Concerns have previously been raised about the vari-
able quality of manufacturer submissions to the STA
process5 and cost-effectiveness estimates generated by
manufacturers are often more favourable than those
provided by independent academic groups.11 This ana-
lysis says nothing about the quality of submissions. But
we would suggest that any potential short comings with
the STA process are not necessarily conﬁned to the inde-
pendence of the health technology assessment (HTA)
dossier; rather they are arguably equally or more likely
to reﬂect restricted scopes, in terms of comparator tech-
nologies, and the relative immaturity of the evidence
base, as STAs are increasingly aligned with a product’s
launch. Whether or not this is true, there remains an
important debate to be had about the speed of HTA
production, the potential trade-off in terms of compre-
hensiveness of the compiled evidence base, and whether
policy recommendations are materially affected.
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CONCLUSION AND RECOMMENDATION
In summary, the evidence suggests that despite the
incorporation of more detailed methods and processes
over the past decade, the time it has taken NICE to
produce guidance over the past decade has not inde-
pendently increased. The introduction of the STA
process has resulted in the production of signiﬁcantly
faster guidance to the NHS, irrespective of the clinical
topic. However, appeals when they occur can signiﬁ-
cantly extend this time. We therefore recommend that
where possible, efforts be made to develop working prac-
tices and processes which can reduce the need for such
appeals.
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